INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY
|
|
- Hollie Roberts
- 6 years ago
- Views:
Transcription
1 INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY
2 Overview MJ BioPharma is a cannabis technology company led by a team of experienced business and medical professionals and researchers. Our expertise lies in extractions and custom formulations. We aim to develop and in-license best in class technologies and products for the medicinal and recreational markets in North America. 2
3 Investment Highlights A pharmaceutical based approach to developing cannabis products for medical and recreational markets Leadership team with international relationships in the fast growing medical and recreational cannabis industry Expertise developing innovative, effective, and precise cannabidiol (CBD), terpene and tetrahydrocannabinol (THC) based products Seeking to acquire or develop, best in class novel technologies and bring them to market Financial partners with experience in funding and creating value for shareholders in cannabis companies 3
4 Our Cannabis Business A revolution is taking place in North America and across the globe and the race to create a better, more sophisticated supply chain with medical grade, quality controlled, custom cannabis products is underway. MJ BioPharma is aiming to establish itself as a leader in this segment by acquiring and developing novel technologies with immediate term commercial applications. We are developing cannabidiol (CBD) delivery technologies such as a sublingual strip and a time release capsule, in addition to a range of oils for the medicinal and recreational markets. 4
5 About MJ BioPharma Vinergy Resources Ltd. (a publicly traded company on the CSE, trading under the symbol VIN) has an agreement to acquire MJ BioPharma with its cannabis assets, and majority interest in a Health Canada and Federal Drug Administration (FDA) licensed lab. Delivery Technologies Along with conventional systems, MJ BioPharma plans to offer the BURST delivery system built on natural botanical polymers delivering specially processed high purity cannabinoid complexes. The unique system for cannabinoid activation maintains the natural balance of THC, CBD, CBN and terpenes potentially delivering it to the body faster than any currently available delivery method. Development Lab Biolennia will provide a host of drug testing services and support to MJ BioPharma s product line. The facilities are already pursuing research and development into novel product formulation, safe extraction systems and complete quality management systems. 5
6 Our Technology Our process and approach set us apart from others in the industry: EXTRACTS We are experts at developing extracts and custom formulations. PRACTICES Our state-of-the-art lab services adhere to the latest standards for GMP, CGMP, ISO, EPA, FDA, CIFA, HACCP, OSHA, WHIMIS, and Health Canada. SCIENCE We use scientific methodology applied to a variety of formulations to achieve desired superior results. MANAGEMENT Our management is comprised of scientists, researchers, biochemists and business management personnel skilled in the development of cannabis and the business. 6
7 Market Key Facts Canada Canada, if legalized, is estimated at $5 billion in cannabis sales annually. US Markets The US market for marijuana in 2015 was $5.4 billion estimated is at $7.6 billion in total sales. Adding new markets legalizing, total could reach $20 billion within 3 years. Sources: *Sources: The Hemp Business Journal; Deloitte; 7
8 Milestones Since entering the cannabis sector MJ BioPharma has made major strides including moving the business in a new direction and establishing the company as a significant participant. DEC 2016 MJ BioPharma announces the signing of letter of intent to be acquired by Vinergy Resources Ltd. JAN 2017 Vinergy, a company for which MJ BioPharma has agreed to an LOI to be acquired, closes $2MM financing JAN 2017 Formed new Scientific Advisory Board (SAB) consisting of leading biopharma technology advisors FEB 2017 Announced BURST technology - a breakthrough in oral delivery of cannabinoids FEB 2017 Acquired 65% of Biolennia Labs, a Health Canada & FDA licensed lab 8
9 Immediate Strategy Through MJ BioPharma Develop our own unique extracts and custom formulations with unique processes and methodologies Develop numerous edible and oil products for the Medical and Recreational space Through Biolennia Labs Carry out R&D, develop and isolate formulations for use in medical and recreational applications. Currently in application process for a dealers license. Expansion Build a California and Nevada-licensed genetics breeding facility with extraction systems Add a dispensary license with our extraction and genetics partners 9
10 Founding Management The founding management of the company have a combined 30 years experience in the scientific, biopharma and cannabis industry. CEO MR.KENT A. DEUTERS Managed over 200 private label products for several Fortune 500 companies. 7 years of experience in the North American cannabis industry Commercialized delivery technologies and custom formulations for US based cannabis companies. DIRECTOR MR.JEREMY TOWNING Over 20 years of financial and real estate market experience Raised over $100MM in funding Extensive experience negotiating and executing on joint ventures SCIENTIFIC ADVISORY BOARD, CHAIR DR. WILL PANENKA M.D. and M.Sc. from the University of Calgary, Canada and Research Fellow, Harvard University. One of two specialists in Western Canada with unique dual specialties of neurology and psychiatry Extensive training and experience in drug use, addictions, and traumatic brain injury. SCIENTIFIC ADVISORY BOARD MR. JOHN SIMON Extensive experience in quality assurance and regulatory affairs under FDA and Health Canada audits of medical device and drug manufacturers, testing facilities, and clinical sites. Helped obtain, renew and maintain Drug Establishment Licenses (DEL), Medical Device Establishment Licenses (MDEL), and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR) 10
11 Summary MJ BioPharma is positioned for diversification into both sides of the business; producing and refining cannabis products with support from experienced financial partners. P
12 Disclaimer IMPORTANT: PLEASE READ The information set forth in this document contains forward-looking statements. Statements in this document, which are not purely historical, are forward looking and include statements regarding beliefs, plans, expectations or intentions regarding the future. Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as estimate, anticipate, believe, plan, intend, expect, may, should, or similar statements are forward-looking statements. Risks and uncertainties for the include, but are not limited to, the risks associated with the impact of general economic conditions in countries in which the conducts business, the impact of competitive products and pricing, product demand and market acceptance, new product development, the continuation and development of key customer and supplier relationships, and the availability of high-quality, qualified personnel and management. Other risks include, but are not limited to, factors affecting development and expansion activities generally including access to capital to meet all of the s financial requirements and the s ability to control costs. There can be no assurance that the s efforts will succeed and the will ultimately achieve sustained commercial success. These forwardlooking statements are made as of the date of this document, and the assumes no obligation to update the forward-looking statements, except as required by applicable securities laws, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the believes that the beliefs, plans, expectations and intentions contained in this document are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. This information contained in the document has been prepared by management of the, who takes full responsibility for its contents. This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the in any jurisdiction. 12
REVOLUTIONIZING HEALTH AND WELLNESS, IMPROVING LIVES WITH CANNABIS
REVOLUTIONIZING HEALTH AND WELLNESS, IMPROVING LIVES WITH CANNABIS State of the Nation Overall Summary 2016 A year of challenges 2017 Q1 - Return to strong growth, operations up and running Q2 - Close
More informationDisclaimers & Cautionary Statements
Disclaimers & Cautionary Statements The information found herein, and any other materials provided by Cronos Group (the Company ), are intended solely for discussion purposes and are not intended as, and
More informationTechnology and Compliance Platform for the Cannabis Industry
Technology and Compliance Platform for the Cannabis Industry MassRoots, Inc. OTCQB: MSRT July 2017 Safe Harbor & Disclaimer This information does not constitute an offer to sell or a solicitation of an
More informationCSC Separating Into Two Industry Leading Public Companies. May 19, 2015
CSC Separating Into Two Industry Leading Public Companies May 19, 2015 Forward looking statements All written or oral statements made by CSC at this meeting or in these presentation materials that do not
More informationOTCQB: KSHB NICK KOVACEVICH OCTOBER 2017
OTCQB: KSHB NICK KOVACEVICH OCTOBER 2017 Important Cautions Regarding Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions
More informationOTCQB: KSHB NICK KOVACEVICH JULY 2017
OTCQB: KSHB NICK KOVACEVICH JULY 2017 Important Cautions Regarding Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of
More informationFor personal use only. Medical Nutrition Investment Company
Medical Nutrition Investment Company Investment Focus Eve s vision is to be a leading Australia Investment company in the rapidly growing Global Medical Nutrition sector. Investing in businesses in the
More informationInvestor Presentation
Investor Presentation March 2018 TSX-V: ABCN 1 Disclaimer Certain information included in this presentation, which was prepared on January 8, 2018 speaks only as of such date, including any information
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationPresentation of 6M Figures BRAIN AG
Presentation of 6M Figures BRAIN AG BRAIN Key Enabler for a Biobased Economy Zwingenberg, May 31, 2016 BRAIN Aktiengesellschaft Zwingenberg Germany www.brain-biotech.de +49 (0) 6251-9331-0 Disclaimer This
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationHPS vs. LED Indoor Cannabis Cultivation. Lasse Schulze (Ph.D.)
HPS vs. LED Indoor Cannabis Cultivation Lasse Schulze (Ph.D.) Disclaimers & Cautionary Statements The information found herein, and any other materials provided by Cronos Group (the Company ), are intended
More informationMEDICAL MARIJUANA: TWEED: WHAT CAN HAPPEN IN A YEAR. TSXV:TWD
MEDICAL MARIJUANA: TWEED: WHAT CAN HAPPEN IN A YEAR. TSXV:TWD DISCLAIMER This presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or advertisement
More informationStrengthening the experience and embracing the shift
Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationSCIENTUS PHARMA. CORPORATE PRESENTATION October 2017
SCIENTUS PHARMA CORPORATE PRESENTATION October 2017 FORWARD-LOOKING STATEMENTS This presentation contains certain forward looking statements and forward looking information (collectively referred to herein
More informationFOR SALE. State-of-the-Art cgmp-qualified Solid Dosage Development and Manufacturing Facility
FOR SALE State-of-the-Art cgmp-qualified Solid Dosage Development and Manufacturing Facility was purchased in 2015 by Ropack Pharma Solutions (RPS). RPS has made the strategic decision to market and sell
More informationAVINO SILVER & GOLD MINES LTD.
April 13, AVINO SILVER & GOLD MINES LTD. T 604.682.3701 Suite 900, 570 Granville Street ir@avino.com F 604.682.3600 Vancouver, BC V6C 3P1 www.avino.com NYSE-MKT: ASM TSX-V: ASM FSE: GV6 AVINO ANNOUNCES
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationTHREE -YEAR STRATEGIC PLAN
THREE -YEAR STRATEGIC PLAN 2017 18 2019 20 About ICES Population-based health research that makes a difference Since its inception in 1992, the Institute for Clinical Evaluative Sciences (ICES) has led
More informationHydro takes over Vale s aluminium business in transforming transaction
Hydro takes over Vale s aluminium business in transforming transaction Svein Richard Brandtzæg, President and CEO Bank of America Merrill Lynch Global Metals & Mining Conference May 12, 2010 (1) Cautionary
More informationValmet unique offering with process technology, automation and services. Investor Lunch March 17, 2016 Kari Saarinen, CFO
Valmet unique offering with process technology, automation and services Investor Lunch Kari Saarinen, CFO Agenda Investor lunch 1 2 Valmet s in brief Investment highlights 3 Area development 4 Conclusions
More informationShareholder Update. April Dear Shareholders,
April 2017 Shareholder Update Brazil Po ta sh Corp, Sui t e 8 00, 6 5 Que e n St re et West, Toronto, O n M 5H 2 M5 www.potassio do bra s il.co m. br Dear Shareholders, During the first quarter of 2017,
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationResponsible Investment in Sustainable Forestry
Responsible Investment in Sustainable Forestry How do asset managers develop and execute RI strategies for timberland? Radha Kuppalli Director, Investor Services New Forests Pty Ltd rkuppalli@newforests.com.au
More informationStrategic Management. One Team. Infinite Solutions.
Strategic Management One Team. Infinite Solutions. Stantec's Strategic Management team combines business, financial, technical, and operational knowledge to develop solutions for our clients' capital
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationInvestor Presentation
Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading
More informationIP Networks & Applications
IP Networks & Applications Creating Value Through Applications & Analytics Bhaskar Gorti President, Applications & Analytics Our market is different from Nokia s Networks businesses 1. More fragmented
More informationOppenheimer 16 th Annual Consumer Conference
Oppenheimer 16 th Annual Consumer Conference Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
More informationInvestor Presentation September 2016
Investor Presentation September 2016 1 LEGAL DISCLAIMER Statements made by representatives for ATCO Ltd. and information provided in this presentation may be considered forward-looking statements. By their
More informationInventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30)
Equity Telecom / Telecom Services Update (December 11, 2015) Inventergy Global, Inc. (NASDAQ: INVT), Target Price: $10.30) Based in Campbell, CA, Inventergy (NASDAQ: INVT, Inventergy ) is an intellectual
More informationLeader in Pharmaceutical Oral Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Oral Films WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation pharmaceutical products that address unmet medical
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationINVESTOR PRESENTATION AUGUST 2017
INVESTOR PRESENTATION AUGUST 2017 Forward Looking Statements The information set forth in this document contains forward-looking statements. Statements in this document, which are not purely historical,
More informationuniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,
More information2017 Annual Meeting of Shareholders
2017 Annual Meeting of Shareholders May 17, 2017 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company s
More information16th Annual ICR XChange Conference January 14, 2014
16th Annual ICR XChange Conference January 14, 2014 Bill DeLaney President, Chief Executive Officer Chris Kreidler Executive Vice President, Chief Financial Officer Forward-Looking Statements Statements
More informationGlobal Manufacturing Industry Landscape
Global Manufacturing Industry Landscape Tim Hanley, Deloitte Global Leader, Consumer & Industrial Products Industry group 2017 Manufacturing Forum. 17 October 2017. Perdue University What we will cover
More informationTo unleash LeasePlan s potential in an exciting and dynamic market, we have defined a three-year strategic plan. Our strategic plan has three goals:
26 LeasePlan annual report 2016 What s next? 2017-2020 Our strategy To unleash LeasePlan s potential in an exciting and dynamic market, we have defined a three-year strategic plan. Our strategic plan has
More informationBirth of a world leader
PRESS RELEASE Birth of a world leader 26 April 2007 Net profit rose 13.6% to 458.2 million in the first quarter of 2007 IBERDROLA IS NOW ONE OF THE WORLD S LARGEST ELECTRICITY COMPANIES WITH THE SCOTTISHPOWER
More informationAugust Teligent, Inc. Jason Grenfell-Gardner CEO Jenniffer Collins CFO. NASDAQ Global Select: TLGT
August 2016, Inc. Jason Grenfell-Gardner CEO Jenniffer Collins CFO NASDAQ Global Select: TLGT Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements
More informationAgilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationDelivering Energy Solutions
Delivering Energy Solutions Meeting Energy Needs Homes and businesses across the country depend on energy to support the economy and sustain a high quality of life. Yet there s also a responsibility to
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationEnactment of the Corporate Governance Policy
[Unofficial Translation] June 1, 2015 Koichiro Watanabe President and Representative Director The Dai-ichi Life Insurance Company, Limited Code: 8750 (TSE First section) Enactment of the Corporate Governance
More informationEnzyme Enabled Carbon Capture
Enzyme Enabled Carbon Capture Lowering the CCS Cost Barrier October 3, 2011 2011 CO2 Solutions Inc. and CO2 Solution Technologies Inc. All rights reserved Important Information About Forward Looking Statements
More informationOUR GUIDING PRINCIPLES
OUR GUIDING PRINCIPLES For some 50 years, the Green Bulletin series described the way John Deere conducted business and put its values into practice. The bulletins served as guides for the judgments and
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationThe Emerging Technology Program: FDA s Perspective
The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical
More informationAPITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS
APITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS HASSELT, Belgium, and CHEPSTOW, UK, 31 October 2017 - Apitope (the Company or Apitope ), a clinical
More informationBUCHANS MINERALS SUCCESSFULLY PRODUCES HIGH PURITY MANGANESE ELECTROLYTE FOR THE PRODUCTION OF ELECTROLYTIC MANGANESE METAL
Head Office 247 Dill Road, RR 1 Windsor, NS, Canada, B0N 2T0 Trading Symbol: TSXV: BMC News Release No. 10-12 Shares Outstanding: 150,898,545 May 3 rd, 2012 T (902) 472 3520 F (902) 472 3521 www.buchansminerals.com
More informationVeterinarians Rely on Pacific Continental Bank
Veterinarians Rely on Pacific Continental Bank Just as veterinarians are committed to their patients welfare, Pacific Continental is committed to the financial health of veterinary clinics. We understand
More informationCB&I Investor Presentation March 2017
A World of Solutions CB&I Investor Presentation March 2017 A Leading Provider of Technology and Infrastructure for the Energy Industry Safe Harbor Statement This presentation contains forward-looking statements
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationcompany overview M A R C H
company overview MARCH 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationBusiness Update: First Quarter 2007
Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements
More informationCITIZEN GREEN TECHNOLOGIES
Presents CITIZEN GREEN TECHNOLOGIES Forward Looking Statements This Presentation (together with any supplements and any other information that may be furnished to prospective investors by Global Cannabis
More informationINVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationFinancial and other information related to the intended combination of Intrum Justitia and Lindorff published by Intrum Justitia
Stockholm 12 June 08:10 CET (page 1 of 5) PRESS RELEASE Intrum Justitia AB (publ) Corporate identity no.:556607-7581 Financial and other information related to the intended combination of Intrum Justitia
More informationHelping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
More informationAn Inbound Marketing & Sales SaaS Company
1 Safe Harbor This presentation includes certain forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning our cash flow and
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationRecommended acquisition of The BSS Group plc. 5 July 2010
Recommended acquisition of The BSS Group plc 5 July 2010 Important information This document is being made available only to persons who fall within the exemptions contained in Article 19 and Article 49
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationJAIBARAS DIAMOND PROJECT UPDATE
JAIBARAS DIAMOND PROJECT UPDATE TSX-V STAR Market Release 11 July 2017 FIVE STAR DIAMONDS LIMITED Av. Jornalista Ricardo Marinho, 360 Ed. Cosmopolitan - Sala 113, CEP 22631-350 Barra da Tijuca - Rio de
More informationEnhancing Audit Committee Excellences through Internal Audit. 21 November 2017
Enhancing Audit Committee Excellences through Internal Audit 21 November 2017 Sharpen and Strengthen Excellences of Audit Committee Recent Trends and Emerging Challenges Global and Emerging Trends Roles
More informationIF YOU WERE LIKE US, THEN YOU RE OVER USING ALL THESE PROGRAMS JUST TO GET TO KNOW YOUR CUSTOMER.
PITCH PRESENTATION 2017 DISCLOSURE This document does not constitute an offer to sell or a solicitation of an offer to buy any securities. This document is an outline of matters for discussion only and
More information121 MINING INVESTMENT CONFERENCE HONG KONG
ASX / MEDIA RELEASE 23 April 2018 121 MINING INVESTMENT CONFERENCE HONG KONG St George Mining Limited (ASX: SGQ) ( St George or the Company ) is participating at the 121 Mining Investment Conference in
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationQuintiles Transnational Corporation Big is Beautiful
Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development
More informationThe Northwest Seaport Alliance Transition Plan DRAFT AS OF 5/5/15
The Northwest Seaport Alliance Transition Plan DRAFT AS OF 5/5/15 1.0 Introduction This document fulfills requirements for a Transition Plan as defined in the Framework ILA. It defines the steps and timeframes
More informationKey Definitions 6/16/2015
Technology Transfer from a CDMO Perspective Joe Cobb, CPIP Director, Pharmaceutical Development Metrics Contract Services, a division of Mayne Pharma US 18-June-2015 Key Definitions CDMO Contract Development/Manufacturing
More informationBemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference
Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference September 14, 2011 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the
More informationIllegal Drugs & Pharma: Kingpins of New Risk
Illegal Drugs & Pharma: Kingpins of New Risk Dan Frechtling, Chief Product Officer, G2 Web Services Dione Hodges, Senior Risk Management Director, Sterling Payment Technologies 03/31/2016 MAC is an organization
More informationTheranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris
This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, South Africa, Canada, Australia or Japan. This press release does not constitute an offer
More informationProcess and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager
Process and Architecture Overview IDMP Identification of Medicinal Products Sven Eller, Life Sciences Solution Engagement Manager Legal Disclaimer The information in this document is confidential and proprietary
More informationLA-Z-BOY INCORPORATED
LA-Z-BOY INCORPORATED November 2017 Providing comfort to America for 90 years FORWARD-LOOKING DISCLAIMER This presentation contains forward-looking statements that involve uncertainties and risks as detailed
More informationCBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES
CBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES CBRE Industrial & Logistics Services represents the largest industrial services platform in the world, offering an integrated suite of advisory,
More informationGroup Management and Productivity Enhancement by Shinsei Bank Group
Management and Productivity Enhancement by Shinsei Bank February, 2018 Akira Hirasawa Chief Officer of Organizational Strategy Headquarters Shinsei Bank, Limited Direction of Management Establish unique
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationNews Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21
Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Even more attractive to life science and fine chemical industries Saltigo GmbH Contact: Ilona Kawan LANXESS AG Corporate Communications
More informationInvestor Presentation February 2018 Slide 1. Investor Presentation February 2018
Investor Presentation February 2018 Slide 1 Investor Presentation February 2018 Forward Looking Statements Statements made during this presentation that set forth expectations, predictions, projections
More informationStrategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical
Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationExecutive Recruitment
Executive Recruitment Design Build Attract No margin for error. The most powerful business decision you will ever make is selecting the executives you hire. There are thousands of executive candidates
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationPOSITION DESCRIPTION June 16, 2017
POSITION DESCRIPTION June 16, 2017 Common Name: Classification: Team / Section: Bureau / Division: ROOFING / BUILDING ENVELOPE PROJECT MANAGER ENGINEERING SPECIALIST MANAGEMENT Project Delivery Services
More informationBreaking the Silo Mentality Working With Opinion Leaders
CBI s 2 nd Annual KOL Conference Breaking the Silo Mentality Working With Opinion Leaders Kashif Chaudhry Objectives Share a view on the changing environment impacting the pharmaceutical industry and KOL
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationAT&T INC. CORPORATE GOVERNANCE GUIDELINES
AT&T INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors of AT&T Inc. ("AT&T") acting on the recommendation of its Corporate Governance and Nominating Committee, has developed and adopted the following
More information